Published in Sci Rep on November 07, 2016
Helicobacter pylori infection and the development of gastric cancer. N Engl J Med (2001) 17.13
Helicobacter pylori virulence and genetic geography. Science (1999) 7.64
Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer (2010) 4.64
Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev (2010) 3.41
The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol (2006) 3.07
Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut (1998) 2.84
Helicobacter pylori evolution and phenotypic diversification in a changing host. Nat Rev Microbiol (2007) 2.71
Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology (2008) 2.63
Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol (2010) 2.56
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
Helicobacter pylori HopH (OipA) and bacterial pathogenicity: genetic and functional genomic analysis of hopH gene polymorphisms. J Infect Dis (2006) 2.02
Serum autoantibodies as biomarkers for early cancer detection. FEBS J (2009) 1.94
Role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiol Rev (2010) 1.73
Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut (2005) 1.62
Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol (2014) 1.51
Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer (2011) 1.45
Role of adherence in interleukin-8 induction in Helicobacter pylori-associated gastritis. Infect Immun (1997) 1.38
Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res (2009) 1.33
Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. Infect Immun (2004) 1.30
Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer Lett (2008) 1.29
Helicobacter pylori virulence and cancer pathogenesis. Future Oncol (2014) 1.21
Vacuolating cytotoxin genotypes are strong markers of gastric cancer and duodenal ulcer-associated Helicobacter pylori strains: a matched case-control study. J Clin Microbiol (2014) 1.20
IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting. Int J Cancer (1996) 1.16
Outer membrane protein expression profile in Helicobacter pylori clinical isolates. Infect Immun (2009) 1.15
Non-invasive tests in gastric diseases. Dig Liver Dis (2008) 1.13
The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun Signal (2013) 1.11
Comparative immunoproteomics of identification and characterization of virulence factors from Helicobacter pylori related to gastric cancer. Mol Cell Proteomics (2006) 1.08
Functional and intracellular signaling differences associated with the Helicobacter pylori AlpAB adhesin from Western and East Asian strains. J Biol Chem (2007) 1.06
Interaction between host gastric Sialyl-Lewis X and H. pylori SabA enhances H. pylori density in patients lacking gastric Lewis B antigen. Am J Gastroenterol (2006) 1.04
Retracted Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes. Clin Sci (Lond) (2006) 1.03
Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics (2012) 1.02
Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries. Future Microbiol (2010) 1.02
Systematic review and meta-analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomes. Gut Pathog (2010) 1.01
Interleukin-1β induced by Helicobacter pylori infection enhances mouse gastric carcinogenesis. Cancer Lett (2013) 0.99
Current issues and future perspectives of gastric cancer screening. World J Gastroenterol (2014) 0.96
Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development. Gut (1999) 0.96
A CagA-independent cluster of antigens related to the risk of noncardia gastric cancer: associations between Helicobacter pylori antibodies and gastric adenocarcinoma explored by multiplex serology. Int J Cancer (2013) 0.95
Association between cag-pathogenicity island in Helicobacter pylori isolates from peptic ulcer, gastric carcinoma, and non-ulcer dyspepsia subjects with histological changes. World J Gastroenterol (2005) 0.94
Comparative proteomics and immunoproteomics of Helicobacter pylori related to different gastric pathologies. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.92
The immune response against Helicobacter pylori--a direct linkage to the development of gastroduodenal disease. Microbes Infect (2000) 0.92
Increasing evidence of the role of Helicobacter pylori SabA in the pathogenesis of gastroduodenal disease. J Infect Dev Ctries (2008) 0.90
Identification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics (2011) 0.90
H. pylori virulence factors: influence on immune system and pathology. Mediators Inflamm (2014) 0.88
Expression of Helicobacter pylori virulence factors and associated expression profiles of inflammatory genes in the human gastric mucosa. Infect Immun (2007) 0.88
Serum anti-Helicobacter pylori immunoglobulin G titer correlates with grade of histological gastritis, mucosal bacterial density, and levels of serum biomarkers. Scand J Gastroenterol (2013) 0.88
An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res (2012) 0.86
A versatile protein microarray platform enabling antibody profiling against denatured proteins. Proteomics Clin Appl (2013) 0.85
Serum Helicobacter pylori NapA antibody as a potential biomarker for gastric cancer. Sci Rep (2014) 0.85
Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm. Helicobacter (2013) 0.85
Proteomic identification of biomarkers related to Helicobacter pylori-associated gastroduodenal disease: challenges and opportunities. J Gastroenterol Hepatol (2008) 0.84
Predominant mucosal IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer. World J Gastroenterol (2013) 0.84
Association of Helicobacter pylori babA2 with peptic ulcer disease and gastric cancer. World J Gastroenterol (2013) 0.84
Outer membrane inflammatory protein A, a new virulence factor involved in the pathogenesis of Helicobacter pylori. Mol Biol Rep (2014) 0.81
Clinical proteomics identifies potential biomarkers in Helicobacter pylori for gastrointestinal diseases. World J Gastroenterol (2014) 0.80
Association of presence/absence and on/off patterns of Helicobacter pylori oipA gene with peptic ulcer disease and gastric cancer risks: a meta-analysis. BMC Infect Dis (2013) 0.79
Antiadhesive properties of arabinogalactan protein from ribes nigrum seeds against bacterial adhesion of Helicobacter pylori. Molecules (2014) 0.78
Analysis of autoantibody profiles in osteoarthritis using comprehensive protein array concepts. J Proteome Res (2014) 0.78
Antibody profiling of bipolar disorder using Escherichia coli proteome microarrays. Mol Cell Proteomics (2014) 0.76
Helicobacter pylori infection in early and advanced gastric adenocarcinoma: a seroprevalence study in 143 Taiwanese patients. Hepatogastroenterology (1993) 0.76
The study of the oipA and dupA genes in Helicobacter pylori strains and their relationship with different gastroduodenal diseases. Gastroenterol Hepatol Bed Bench (2015) 0.76
High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol (2014) 0.99
Deep-sea water containing selenium provides intestinal protection against duodenal ulcers through the upregulation of Bcl-2 and thioredoxin reductase 1. PLoS One (2014) 0.78
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol (2009) 0.78